FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:210-211 January 17, 2002 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: The study by Macdonald and colleagues (Sept. 6 issue)¹ is commendable for its duration, detailed analysis, and quality control. However, we believe that the authors should have randomly assigned the patients to one of the two study groups before surgery. The definitions of resectability and stratification according to tumor stage are meaningless because the surgical approach was not uniform. Moreover, the conclusion that postoperative chemoradiotherapy should be considered for all patients at high risk for recurrence does not correlate with the aims of the study. There appears to have been a substantial number of major side effects . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Cascinu, S., Labianca, R., Barone, C., Santoro, A., Carnaghi, C., Cassano, A., Beretta, G. D., Catalano, V., Bertetto, O., Barni, S., Frontini, L., Aitini, E., Rota, S., Torri, V., Floriani, I. (2007). Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI J Natl Cancer Inst 99: 601-607 [Abstract] [Full Text]